We are #1 in Single Inhaler Triple Therapy market.
We have a stronghold in the respiratory therapy segment and are also contributing significantly to the India business. We possess a robust portfolio consisting of inhalers (DPI and MDI), nebulization solutions, oral medications, nasal sprays, pediatric care, and devices.
We are #1 in Single Inhaler Triple Therapy market.
We rank #2 in the Indian respiratory market.
We are rapidly strengthening our respiratory portfolio, especially inhalation therapies and advanced devices, with a focus on development of innovative products.
We are addressing unmet needs to improve patient outcomes through better physician awareness, patient education, and early access to diagnosis.
We at Lupin command a significant position in asthma and COPD management with brands like Budamate, Telekast, AB-Flo, and Difizma, which is India’s 1st Ultra LABA + LAMA + ICS.
Our brand Vilfuro-G is the world’s first fixed dose triple DPI combination in its category for COPD.
We are also focused on accelerated development of our inhalation pipeline and development of green propellant programs for our ongoing commitment to environmental sustainability.
Our respiratory portfolio addresses a broad spectrum of disorders with a focus on long-term respiratory disease management and improved patient healthcare outcomes.
A chronic lung disease which causes restriction in flow throughout airways and gradual lung damage, caused generally due to exposure to smoke, pollutants and fumes leading to chronic cough, chest tightness, shortness of breath, and coughing.
A chronic lung condition in which the airways become narrowed and inflamed, leading to breathing difficulty, coughing, wheezing, and shortness of breath.
A condition caused by inflammation of the nasal passages due to airborne allergens, resulting in symptoms such as nasal congestion, itching, and fatigue.
Disclaimer: The content on this website/webpage relates to a specific therapy/therapeutic area and is intended solely for informational and educational purposes for healthcare professionals and patients across India and other global locations, is not intended to substitute professional medical advice, diagnosis, or treatment. Advice from a physician or other qualified healthcare professional must be sought for any queries regarding a medical condition or treatment. Information on this website/webpage should not be solely used or relied upon in the absence of or delay in receiving professional medical advice. While Lupin makes reasonable efforts to ensure that the information is accurate and up to date, it makes no representations or warranties regarding its completeness or accuracy and accepts no liability for reliance on such information. The information on this website/webpage is not a substitute for prescribing information or patient information leaflets accompanying any medicinal product. The information on this website/webpage is subject to change without notice and may not reflect the most current medical, scientific, or regulatory developments. All content on this website/webpage is the intellectual property of Lupin and shall not be reproduced, modified, distributed, or used for any commercial purpose without the prior written consent of Lupin.
Our respiratory portfolio includes a broad range of inhalation therapies, specialty medicines, and drug-device solutions designed for both acute and long-term respiratory care.
Used for treatment of asthma and COPD. It regulates mucus clearance and acts as a bronchodilator and anti-inflammatory.
Combination of montelukast and levocetirizine, mainly used for allergies with symptoms like runny or blocked nose, sneezing, itching, swelling, watery eyes, and congestion. It makes breathing easier by reducing inflammation in airways.
An antihistamine that relieves allergy symptoms such as sneezing, itching, watery eyes, and a runny nose.
Used to treat respiratory conditions involving dense mucus. It works by thinning mucus in the airways, making it easier to cough up, and improve breathing.
Used to treat dry, non-productive cough by acting as an antitussive. It suppresses the cough by reducing the activity of the cough center in the brain.
Our journey is marked by pioneering launches, transformative patient programs, and sustained contributions to respiratory care.
At Lupin, we remain committed to advancing respiratory health through novel inhalation technologies, high-quality medicines, and initiatives that support patients and healthcare professionals.
Our continued investment in research, digital tools, and next-generation therapies aim to improve respiratory outcomes and help patients breathe easier every day.
